ClinicalTrials.gg
Active, not recruitingNCT02453282MYSTICUpdated Aug 6, 2026Results posted

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of MEDI4736 (Durvalumab) and MEDI4736 (Durvalumab)+Tremelimumab in Non-Small-Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca. Active, not recruiting at 196 sites in 17 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,118
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
3rd of 94
1,118 · median 74
Started
2015
with 6 others
Phase 3
17 of 94
3 open now
Primary completion
2018-10
later than 0 of 36 live
Registered
12th of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is one of 7 that started in 2015, is one of 17 in phase 3, reaches primary completion later than 0 of the 36 other live ones, and was the 12th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC

Read the detailed description

Patients will be randomized in a 1:1:1 ratio to receive treatment with MEDI4736 + tremelimumab combination therapy, MEDI4736 monotherapy, or Standard of Care (SoC) therapy.

03

Conditions studied

  • Non-Small-Cell Lung Carcinoma NSCLC

Keywords

  • NSCLC, PD-L1, MEDI4736, Tremelimumab, PFS, OS
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For inclusion in the study, patients should fulfill the following criteria:

  • Aged at least 18 years
  • Documented evidence of Stage IV NSCLC
  • No sensitizing EGFR mutation or ALK rearrangement
  • No prior chemotherapy or any other systemic therapy for recurrent/ NSCLC
  • World Health Organization (WHO) Performance Status of 0 or 1

Exclusion criteria

Exclusion Criteria:

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

  1. Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant
  2. or spinal cord compression unless asymptomatic, treated and stable (not requiring )
  3. Prior exposure to Immunomodulatory therapy (IMT), including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines
  4. Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease]
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,118 participants (actual)

Study arms

  • Experimental
    Monotherapy

    PD-L1 monoclonal Antibody monotherapy.

    Biological: MEDI4736 (Durvalumab)

  • Experimental
    Combination Therapy

    PD-L1+Tremelimumab combination therapy

    Biological: MEDI4736 (Durvalumab)+Tremelimumab · Biological: Tremelimumab

  • Active comparator
    Standard of Care

    Standard of Care chemotherapy treatment

    Drug: Paclitaxel + Carboplatin · Drug: Gemcitabine + Cisplatin · Drug: Gemcitabine + Carboplatin · Drug: Pemetrexed + Cisplatin · Drug: Pemetrexed + Carboplatin

Interventions

  • BiologicalMEDI4736 (Durvalumab)+Tremelimumab

    Drug page: Durvalumab

  • DrugPaclitaxel + Carboplatin

    Drug pages: Paclitaxel · Carboplatin

    Chemotherapy Agents

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugGemcitabine + Cisplatin

    Drug pages: Gemcitabine · Cisplatin

    Chemotherapy Agents

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugGemcitabine + Carboplatin

    Drug pages: Gemcitabine · Carboplatin

    Chemotherapy Agents

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugPemetrexed + Cisplatin

    Drug pages: Pemetrexed · Cisplatin

    Chemotherapy Agents

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugPemetrexed + Carboplatin

    Drug pages: Pemetrexed · Carboplatin

    Chemotherapy Agents

    Also known as: Platinum based Standard of Care Chemotherapy

  • BiologicalTremelimumab
06

What researchers measure

Primary outcomes

  1. Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).

  2. Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy

    The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of at least 5 millimeter (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).

Secondary outcomes

  1. OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).

  2. OS; PD-L1 (TC >=1%) Analysis Set Population

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).

  3. OS; FAS Population

    The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).

  4. PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy

    The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).

  5. PFS; PD-L1 (TC >=1%) Analysis Set Population

    The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).

  6. PFS; FAS Population

    The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).

  7. Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population

    The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of Complete Response (CR) or Partial Response (PR). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).

  8. ORR; PD-L1 (TC >=1%) Analysis Set Population

    The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).

  9. ORR; FAS Population

    The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).

  10. Duration of Response (DoR); PD-L1 (TC >=25%) Analysis Set Population

    The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).

  11. DoR; PD-L1 (TC >=1%) Analysis Set Population

    The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).

  12. DoR; FAS Population

    The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).

  13. Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population

    The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 12 months.

  14. Percentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population

    The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 12 months.

  15. Percentage of Participants APF12; FAS Population

    The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to 12 months.

  16. Time From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population

    The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).

  17. PFS2; PD-L1 (TC >=1%) Analysis Set Population

    The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).

  18. PFS2; FAS Population

    The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.

    Time frame: Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).

  19. Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months

    Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items with higher scores representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change is defined as an absolute change in the score from baseline of \>=10.

    Time frame: At baseline then every 4 weeks for the first 8 weeks relative to the date of randomization, then every 8 weeks until second progression/death, whichever comes first. Assessed up to 12 months.

  20. Serum Concentrations of Durvalumab

    Blood samples were collected to determine the serum concentration of durvalumab.

    Time frame: Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, and at follow-up Month 3.

  21. Serum Concentrations of Tremelimumab

    Blood samples were collected to determine the serum concentration of tremelimumab.

    Time frame: Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3.

  22. Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab

    Blood samples were collected to determine the Cmax\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.

    Time frame: Within 1 hour after end of infusion on infusion day at Week 12.

  23. Cmax_ss of Tremelimumab

    Blood samples were collected to determine the Cmax\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.

    Time frame: Within 1 hour after end of infusion on infusion day at Week 12.

  24. Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab

    Blood samples were collected to determine the Ctrough\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose at Week 12.

  25. Ctrough_ss of Tremelimumab

    Blood samples were collected to determine the Ctrough\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.

    Time frame: Pre-dose at Week 12.

  26. Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab

    Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against durvalumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

    Time frame: At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment.

  27. Number of Participants With ADA Response to Tremelimumab

    Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against tremelimumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

    Time frame: At Weeks 0 and 12; 3 and 6 months after last dose of study treatment.

07

Results

Posted Nov 29, 2019

Participant flow

A total of 194 centers across 17 countries in Asia, Australia, Europe and North America randomized adults with epidermal growth factor receptor and anaplastic lymphoma kinase wild-type advanced or metastatic non-small cell lung cancer in this study. First participant was randomized on 14 August 2015 and final data cut-off date was 04 October 2018.

Participant flow — Overall Study
MilestoneDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
Started374372372
Received treatment369371352
Completed000
Not completed374372372
Withdrew: Death275277296
Withdrew: Lost to follow-up102
Withdrew: Withdrawal by subject121011
Withdrew: Participants ongoing at data cut-off858462
Withdrew: Other111

Outcome measures

PrimaryOverall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Median · months
Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy16.3 (12.2 to 20.8)11.9 (9.0 to 17.7)12.9 (10.5 to 15.0)
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Log Rank · p = 0.036 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.76 · 97.54% CI 0.564 to 1.019The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Log Rank · p = 0.202 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.85 · 98.77% CI 0.611 to 1.173The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
PrimaryProgression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy

The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of at least 5 millimeter (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Median · months
Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy
monthsDurvalumab + TremelimumabSoC Chemotherapy
Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy3.9 (2.8 to 5.0)5.4 (4.6 to 5.8)
Statistical analysis
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Log Rank · p = 0.705 (The analysis was performed using stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 1.05 · 99.5% CI 0.722 to 1.534The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
SecondaryOS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Median · months
OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy16.3 (12.2 to 20.8)11.9 (9.0 to 17.7)12.9 (10.5 to 15.0)
Statistical analysis
  • Durvalumab Monotherapy vs Durvalumab + Tremelimumab · Log Rank · p = 0.523 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 1.09 · 95% CI 0.836 to 1.421The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
SecondaryOS; PD-L1 (TC >=1%) Analysis Set Population

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Median · months
OS; PD-L1 (TC >=1%) Analysis Set Population
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
OS; PD-L1 (TC >=1%) Analysis Set Population14.6 (10.5 to 17.7)10.9 (9.1 to 13.5)12.3 (10.6 to 14.6)
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Log Rank · p = 0.194 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.88 · 95% CI 0.725 to 1.067The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Log Rank · p = 0.952 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 1.01 · 95% CI 0.834 to 1.213The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab Monotherapy vs Durvalumab + Tremelimumab · Log Rank · p = 0.218 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 1.13 · 95% CI 0.931 to 1.371The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
SecondaryOS; FAS Population

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Median · months
OS; FAS Population
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
OS; FAS Population12.3 (10.1 to 14.9)11.2 (9.5 to 12.9)11.8 (10.5 to 13.3)
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Log Rank · p = 0.602 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.96 · 95% CI 0.812 to 1.128The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Log Rank · p = 0.430 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.94 · 95% CI 0.794 to 1.103The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab Monotherapy vs Durvalumab + Tremelimumab · Log Rank · p = 0.802 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.98 · 95% CI 0.828 to 1.157The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
SecondaryPFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy

The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Median · months
PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy4.7 (3.1 to 6.3)3.9 (2.8 to 5.0)5.4 (4.6 to 5.8)
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Log Rank · p = 0.324 (The analysis was performed using stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.87 · 95% CI 0.667 to 1.143The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab Monotherapy vs Durvalumab + Tremelimumab · Log Rank · p = 0.207 (The analysis was performed using stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 1.18 · 95% CI 0.911 to 1.541The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
SecondaryPFS; PD-L1 (TC >=1%) Analysis Set Population

The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Median · months
PFS; PD-L1 (TC >=1%) Analysis Set Population
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
PFS; PD-L1 (TC >=1%) Analysis Set Population3.6 (2.8 to 4.2)2.8 (2.5 to 3.4)5.5 (4.9 to 5.7)
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Log Rank · p = 0.383 (The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 1.09 · 95% CI 0.894 to 1.339The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Log Rank · p = 0.001 (The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 1.38 · 95% CI 1.136 to 1.678The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab Monotherapy vs Durvalumab + Tremelimumab · Log Rank · p = 0.138 (The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 1.16 · 95% CI 0.954 to 1.403The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
SecondaryPFS; FAS Population

The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Median · months
PFS; FAS Population
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
PFS; FAS Population2.8 (2.6 to 3.1)2.9 (2.6 to 3.4)5.4 (4.8 to 5.6)
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Log Rank · p = 0.015 (The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 1.24 · 95% CI 1.043 to 1.475The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Log Rank · p = 0.010 (The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 1.25 · 95% CI 1.054 to 1.485The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab Monotherapy vs Durvalumab + Tremelimumab · Log Rank · p = 0.984 (The analysis was performed using stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 1.00 · 95% CI 0.845 to 1.179The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
SecondaryObjective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population

The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of Complete Response (CR) or Partial Response (PR). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Number · percentage of participants
Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population
percentage of participantsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population35.634.437.7
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Regression, Logistic · p = 0.698 (P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.) · Odds ratio (or): 0.91 · 95% CI 0.582 to 1.437The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Regression, Logistic · p = 0.534 (P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.) · Odds ratio (or): 0.87 · 95% CI 0.549 to 1.363The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.
  • Durvalumab Monotherapy vs Durvalumab + Tremelimumab · Regression, Logistic · p = 0.820 (P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.) · Odds ratio (or): 0.95 · 95% CI 0.601 to 1.496The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.
SecondaryORR; PD-L1 (TC >=1%) Analysis Set Population

The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Number · percentage of participants
ORR; PD-L1 (TC >=1%) Analysis Set Population
percentage of participantsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
ORR; PD-L1 (TC >=1%) Analysis Set Population26.525.333.6
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Regression, Logistic · p = 0.050 (P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.) · Odds ratio (or): 0.69 · 95% CI 0.480 to 1.000The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (\>=25% Vs \<25%), with 95% CI calculated by profile likelihood.
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Regression, Logistic · p = 0.029 (P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.) · Odds ratio (or): 0.67 · 95% CI 0.464 to 0.959The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (\>=25% Vs \<25%), with 95% CI calculated by profile likelihood.
  • Durvalumab Monotherapy vs Durvalumab + Tremelimumab · Regression, Logistic · p = 0.887 (P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.) · Odds ratio (or): 0.97 · 95% CI 0.661 to 1.430The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (\>=25% Vs \<25%), with 95% CI calculated by profile likelihood.
SecondaryORR; FAS Population

The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Number · percentage of participants
ORR; FAS Population
percentage of participantsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
ORR; FAS Population22.224.730.1
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Regression, Logistic · p = 0.012 (P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.) · Odds ratio (or): 0.65 · 95% CI 0.462 to 0.908The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (\>=25% Vs \<25%), with 95% CI calculated by profile likelihood.
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Regression, Logistic · p = 0.093 (P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.) · Odds ratio (or): 0.76 · 95% CI 0.543 to 1.048The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous) and PD-L1 status (\>=25% Vs \<25%), with 95% CI calculated by profile likelihood.
  • Durvalumab Monotherapy vs Durvalumab + Tremelimumab · Regression, Logistic · p = 0.406 (P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.) · Odds ratio (or): 1.16 · 95% CI 0.818 to 1.647The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous) and PD-L1 status (\>=25% Vs \<25%), with 95% CI calculated by profile likelihood.
SecondaryDuration of Response (DoR); PD-L1 (TC >=25%) Analysis Set Population

The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Median · months
Duration of Response (DoR); PD-L1 (TC >=25%) Analysis Set Population
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
Duration of Response (DoR); PD-L1 (TC >=25%) Analysis Set PopulationNA (4.9 to NA)NA (4.2 to NA)4.4 (2.9 to 7.2)
SecondaryDoR; PD-L1 (TC >=1%) Analysis Set Population

The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Median · months
DoR; PD-L1 (TC >=1%) Analysis Set Population
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
DoR; PD-L1 (TC >=1%) Analysis Set PopulationNA (5.5 to NA)NA (5.6 to NA)4.4 (2.8 to 8.4)
SecondaryDoR; FAS Population

The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Reported as:
Median · months
DoR; FAS Population
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
DoR; FAS PopulationNA (5.5 to NA)NA (4.7 to NA)4.3 (2.8 to 8.4)
SecondaryPercentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population

The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 12 months.
Reported as:
Number · percentage of participants
Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population
percentage of participantsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population32.3 (24.8 to 39.9)25.8 (18.9 to 33.1)14.3 (8.4 to 21.7)
SecondaryPercentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population

The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 12 months.
Reported as:
Number · percentage of participants
Percentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population
percentage of participantsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
Percentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population27.0 (21.6 to 32.6)20.4 (15.7 to 25.5)14.9 (10.2 to 20.5)
SecondaryPercentage of Participants APF12; FAS Population

The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to 12 months.
Reported as:
Number · percentage of participants
Percentage of Participants APF12; FAS Population
percentage of participantsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
Percentage of Participants APF12; FAS Population22.5 (18.1 to 27.1)19.8 (15.6 to 24.4)13.8 (9.7 to 18.6)
SecondaryTime From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population

The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).
Reported as:
Median · months
Time From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
Time From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population12.7 (9.4 to 16.1)10.9 (7.9 to 14.1)10.4 (9.0 to 12.5)
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Log Rank · p = 0.030 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.76 · 95% CI 0.597 to 0.975The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Log Rank · p = 0.045 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.78 · 95% CI 0.606 to 0.994The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
SecondaryPFS2; PD-L1 (TC >=1%) Analysis Set Population

The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).
Reported as:
Median · months
PFS2; PD-L1 (TC >=1%) Analysis Set Population
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
PFS2; PD-L1 (TC >=1%) Analysis Set Population10.6 (8.0 to 12.7)9.4 (7.8 to 11.4)10.5 (9.4 to 11.7)
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Log Rank · p = 0.255 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.90 · 95% CI 0.746 to 1.080The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Log Rank · p = 0.534 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.94 · 95% CI 0.787 to 1.132The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
SecondaryPFS2; FAS Population

The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.

Time frame:
Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).
Reported as:
Median · months
PFS2; FAS Population
monthsDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
PFS2; FAS Population9.3 (7.9 to 10.6)9.8 (8.8 to 11.4)10.1 (9.3 to 10.8)
Statistical analysis
  • Durvalumab Monotherapy vs SoC Chemotherapy · Log Rank · p = 0.663 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.97 · 95% CI 0.824 to 1.131The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
  • Durvalumab + Tremelimumab vs SoC Chemotherapy · Log Rank · p = 0.103 (The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.) · Hazard ratio (hr): 0.88 · 95% CI 0.746 to 1.027The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (\>=25% Vs \<25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.
SecondaryChange From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months

Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items with higher scores representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change is defined as an absolute change in the score from baseline of \>=10.

Time frame:
At baseline then every 4 weeks for the first 8 weeks relative to the date of randomization, then every 8 weeks until second progression/death, whichever comes first. Assessed up to 12 months.
Reported as:
Mean · units on a scale
Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months
units on a scaleDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
EORTC QLQ-C30: Fatigue1.2 ± 1.83-1.1 ± 1.9210.6 ± 2.34
EORTC QLQ-C30: Appetite loss-3.9 ± 2.242.4 ± 2.378.0 ± 2.83
EORTC QLQ-LC13: Dyspnoea2.3 ± 1.510.8 ± 1.605.6 ± 1.90
EORTC QLQ-LC13: Cough-11.4 ± 1.88-5.9 ± 2.01-7.1 ± 2.54
EORTC QLQ-LC13: Chest pain0.1 ± 1.711.6 ± 1.801.7 ± 2.04
SecondarySerum Concentrations of Durvalumab

Blood samples were collected to determine the serum concentration of durvalumab.

Time frame:
Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, and at follow-up Month 3.
Reported as:
Mean · microgram per milliliter (mcg/mL)
Serum Concentrations of Durvalumab
microgram per milliliter (mcg/mL)Durvalumab MonotherapyDurvalumab + Tremelimumab
At Week 0: Pre-infusionNA ± NANA ± NA
At Week 0: End of infusion484.5 ± 210.50444.3 ± 150.29
At Week 12: Pre-infusion139.5 ± 124.98140.8 ± 146.25
At Week 12: End of infusion625.3 ± 453.8506.1 ± 231.89
At Week 24: Pre-infusion163.0 ± 170.04197.0 ± 228.79
At Week 24: End of infusion598.2 ± 344.52553.2 ± 193.33
At follow-up Month 349.3 ± 132.5441.4 ± 131.71
SecondarySerum Concentrations of Tremelimumab

Blood samples were collected to determine the serum concentration of tremelimumab.

Time frame:
Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3.
Reported as:
Mean · mcg/mL
Serum Concentrations of Tremelimumab
mcg/mLDurvalumab + Tremelimumab
At Week 0: Pre-infusionNA ± NA
At Week 0: End of infusion22.6 ± 14.84
At Week 12: Pre-infusion4.9 ± 4.16
At Week 12: End of infusion24.8 ± 10.43
At follow-up Month 30.5 ± 0.42
SecondaryMaximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab

Blood samples were collected to determine the Cmax\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.

Time frame:
Within 1 hour after end of infusion on infusion day at Week 12.
Reported as:
Mean · mcg/mL
Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab
mcg/mLDurvalumab MonotherapyDurvalumab + Tremelimumab
Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab625.3 ± 453.80506.1 ± 231.89
SecondaryCmax_ss of Tremelimumab

Blood samples were collected to determine the Cmax\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.

Time frame:
Within 1 hour after end of infusion on infusion day at Week 12.
Reported as:
Mean · mcg/mL
Cmax_ss of Tremelimumab
mcg/mLDurvalumab + Tremelimumab
Cmax_ss of Tremelimumab24.8 ± 10.43
SecondaryTrough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab

Blood samples were collected to determine the Ctrough\_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose at Week 12.
Reported as:
Mean · mcg/mL
Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab
mcg/mLDurvalumab MonotherapyDurvalumab + Tremelimumab
Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab139.5 ± 124.98140.8 ± 146.25
SecondaryCtrough_ss of Tremelimumab

Blood samples were collected to determine the Ctrough\_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.

Time frame:
Pre-dose at Week 12.
Reported as:
Mean · mcg/mL
Ctrough_ss of Tremelimumab
mcg/mLDurvalumab + Tremelimumab
Ctrough_ss of Tremelimumab4.9 ± 4.16
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab

Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against durvalumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

Time frame:
At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment.
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab
ParticipantsDurvalumab MonotherapyDurvalumab + Tremelimumab
ADA positive at any time1714
Treatment-emergent ADA positive88
ADA positive at baseline and post-baseline31
ADA positive at post-baseline only88
ADA positive at baseline only65
Treatment-boosted ADA00
Persistent positive89
Transient positive30
nAb positive at any visit21
SecondaryNumber of Participants With ADA Response to Tremelimumab

Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against tremelimumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.

Time frame:
At Weeks 0 and 12; 3 and 6 months after last dose of study treatment.
Reported as:
Count of participants · Participants
Number of Participants With ADA Response to Tremelimumab
ParticipantsDurvalumab + Tremelimumab
ADA positive at any time33
Treatment-emergent ADA positive28
ADA positive at baseline and post-baseline1
ADA positive at post-baseline only28
ADA positive at baseline only4
Treatment-boosted ADA0
Persistent positive25
Transient positive4
nAb positive at any visit25

Adverse events

Collected over From first administration of study treatment up to 90 days after last dose of durvalumab and tremelimumab or 30 days after last dose of SoC or date of initiation of the first subsequent therapy, whichever occurs first, approximately 3 years. All-cause mortality, from screening up to data cut-off date (approximately 3 years 1 month).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab Monotherapy278/374 (74.3%)131/369 (35.5%)335/369 (90.8%)
Durvalumab + Tremelimumab278/372 (74.7%)178/371 (48%)328/371 (88.4%)
SoC Chemotherapy297/372 (79.8%)112/352 (31.8%)332/352 (94.3%)
Most frequent serious events
Showing 10 of 261
Most frequent serious events
EventDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
PneumoniaInfections and infestations20/36921/37119/352
AnaemiaBlood and lymphatic system disorders1/3694/37114/352
DiarrhoeaGastrointestinal disorders2/36912/3716/352
PneumonitisRespiratory, thoracic and mediastinal disorders5/3699/3711/352
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/3696/3718/352
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/3697/3710/352
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders2/3697/3710/352
PancytopeniaBlood and lymphatic system disorders0/3690/3716/352
DyspnoeaRespiratory, thoracic and mediastinal disorders6/3696/3712/352
Pleural effusionRespiratory, thoracic and mediastinal disorders6/3695/3711/352
Most frequent other events
Showing 10 of 894
Most frequent other events
EventDurvalumab MonotherapyDurvalumab + TremelimumabSoC Chemotherapy
NauseaGastrointestinal disorders46/36978/371143/352
AnaemiaBlood and lymphatic system disorders36/36933/371136/352
Decreased appetiteMetabolism and nutrition disorders73/36989/37178/352
ConstipationGastrointestinal disorders62/36959/37183/352
FatigueGeneral disorders65/36980/37180/352
VomitingGastrointestinal disorders28/36930/37174/352
DiarrhoeaGastrointestinal disorders51/36974/37141/352
NeutropeniaBlood and lymphatic system disorders6/3692/37165/352
PruritusSkin and subcutaneous tissue disorders42/36967/37117/352
RashSkin and subcutaneous tissue disorders39/36957/37140/352

Baseline characteristics

Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.

Age, Continuous
Age, Continuous(years)Durvalumab MonotherapyDurvalumab + TremelimumabSoC ChemotherapyTotal
Mean63.2 ± 10.3064.3 ± 9.5263.6 ± 9.3663.7 ± 9.74
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab MonotherapyDurvalumab + TremelimumabSoC ChemotherapyTotal
Female118106122346
Male256266250772
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Durvalumab MonotherapyDurvalumab + TremelimumabSoC ChemotherapyTotal
Hispanic or Latino1513634
Not Hispanic or Latino3593583661083
Unknown or Not Reported0101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab MonotherapyDurvalumab + TremelimumabSoC ChemotherapyTotal
White243249243735
Black or African American33410
Asian125118120363
Native Hawaiian or other Pacific Islander0022
Other3137
Missing0101
08

Study locations

196 sites
  • Research Site
    Scottsdale, Arizona 85259, United States
  • Research Site
    Tucson, Arizona 85715, United States
  • Research Site
    Yuma, Arizona 85364, United States
  • Research Site
    Bakersfield, California 93309, United States
  • Research Site
    Fullerton, California 92835, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Los Angeles, California 90024, United States
  • Research Site
    Los Angeles, California 90073, United States
  • Research Site
    Redondo Beach, California 90277, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    San Luis Obispo, California 93401, United States
  • Research Site
    Santa Maria, California 93454, United States
  • Research Site
    West Hollywood, California 90048, United States
  • Research Site
    New Haven, Connecticut 06519, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Pembroke Pines, Florida 33028, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Honolulu, Hawaii 96819, United States
  • Research Site
    Baltimore, Maryland 21231, United States
  • Research Site
    Minneapolis, Minnesota 55435, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Omaha, Nebraska 68198, United States
  • Research Site
    Summit, New Jersey 07901, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    North Charleston, South Carolina 29406, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Richmond, Virginia 23298, United States
  • Research Site
    Madison, Wisconsin 53705, United States
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Gosford, 2250, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Port Macquarie, 2444, Australia
  • Research Site
    Southport, 4215, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Duffel, 2570, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Greater Sudbury, Ontario P3E 5J1, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    Newmarket, Ontario L3Y 2P9, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Saint Catherines, Ontario L2R 6P9, Canada
  • Research Site
    Sault Ste. Marie, Ontario P6A 0A8, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Regina, Saskatchewan S4T 7T1, Canada
  • Research Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Créteil, 94010, France
  • Research Site
    Lille, 59000, France
  • Research Site
    Lyon, 69373, France
  • Research Site
    Marseille, 13915, France
  • Research Site
    Aachen, 52074, Germany
  • Research Site
    Bad Berka, 99437, Germany
  • Research Site
    Berlin, 10967, Germany
  • Research Site
    Berlin, 12351, Germany
  • Research Site
    Freiburg im Breisgau, 79106, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Hamburg, 20251, Germany
  • Research Site
    Heidelberg, 69126, Germany
  • Research Site
    Hemer, 58675, Germany
  • Research Site
    Homburg/Saar, 66421, Germany
  • Research Site
    Immenhausen, 34376, Germany
  • Research Site
    Löwenstein, 74245, Germany
  • Research Site
    Lübeck, 23538, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Oldenburg, 26121, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Velbert, 42551, Germany
  • Research Site
    Würzburg, 97080, Germany
  • Research Site
    Budapest, 1121, Hungary
  • Research Site
    Deszk, 6772, Hungary
  • Research Site
    Edelény, 3780, Hungary
  • Research Site
    Kaposvár, 7400, Hungary
  • Research Site
    Kecskemét, 6000, Hungary
  • Research Site
    Miskolc, 3529, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Pécs, 7624, Hungary
  • Research Site
    Székesfehérvár, 8000, Hungary
  • Research Site
    Genova, 16100, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    San Giovanni Rotondo, 71013, Italy
  • Research Site
    Siena, 53100, Italy
  • Research Site
    Fukushima, 960-1295, Japan
  • Research Site
    Himeji-shi, 670-8520, Japan
  • Research Site
    Hirakata-shi, 573-1191, Japan

Showing the first 100 of 196 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Garon EB, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, Robinet G, Le Moulec S, Natale R, Schneider J, Shepherd FA, Garassino MC, Geater SL, Szekely ZP, Van Ngoc T, Liu F, Scheuring U, Patel N, Peters S, Rizvi NA. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clin Lung Cancer. 2021 Jul;22(4):301-312.e8. doi: 10.1016/j.cllc.2021.02.010. Epub 2021 Feb 19. PubMed 33775558 ↗
  • Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S; MYSTIC Investigators. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 May 1;6(5):661-674. doi: 10.1001/jamaoncol.2020.0237. PubMed 32271377 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Oct 2018, 38 months.

Results were first posted in Nov 2019, 1 year 1 month after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 38 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2015
First posted
May 25, 2015
StartActual
Jul 21, 2015
Primary completionActual
Oct 4, 2018
CompletionEst.
Dec 31, 2026
Results first posted
Nov 29, 2019
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02453282
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 25, 2015
Start date
Jul 21, 2015
Primary completion
Oct 4, 2018
Completion
Dec 31, 2026 (estimated)
Results posted
Nov 29, 2019
Last update
Aug 6, 2026

Study contacts

Stuart McIntosh, MD
study director · AstraZeneca, Alderley Park, Cheshire, UK
Naiyer Rizvi, MD
principal investigator · Columbia University Medical Center, New York, NY, USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion